| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/06/2006 | US7056904 Therapy for bone disorders; osteoporosis; vitamin deficiency |
| 06/06/2006 | US7056900 Disaccharide derivatives for treating hyperglycaemia |
| 06/06/2006 | US7056899 Disaccharide derivatives for treating hyperglycaemia |
| 06/06/2006 | US7056895 1-(3,4-dihydroxy-5-methylol-tetrahydrofur-2-yl),3-amidino-1H-1,2,4- triazoles; infections, infestations, autoimmune diseases; anticarcinogenic and -tumor agents; HIV, hepatitis C, human papilloma virus and giant cell arteritis |
| 06/06/2006 | US7056892 Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| 06/06/2006 | US7056884 Reduced FK228 and use thereof |
| 06/06/2006 | US7056734 Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof |
| 06/06/2006 | US7056720 LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies |
| 06/06/2006 | US7056712 Administering to the individual therapeutically effective amount of human acid alpha-glucosidase at regular interval for therapy of glycogen storage disease type II |
| 06/06/2006 | US7056662 Reducing the level of circulating free fatty acids by administering a compound that inhibits mal1, especially inhibiting transcription or translation of mal1 |
| 06/06/2006 | US7056514 Partial peptide mimetics and methods |
| 06/06/2006 | CA2449892C Nutritional supplement to treat macular degeneration |
| 06/06/2006 | CA2417686C Manufacture of oral dosage forms delivering both immediate release and sustained release drugs |
| 06/06/2006 | CA2327723C Bicyclic hydroxamic acid derivatives |
| 06/06/2006 | CA2158973C 1,5-benzodiazepine derivatives having cck antagonistic or agonistic activity |
| 06/06/2006 | CA2053288C Expression of human apolipoproteins ai and ai-milano in yeast |
| 06/01/2006 | WO2006058303A2 Modulators of muscarinic receptors |
| 06/01/2006 | WO2006058199A1 Methods of modulating high-density lipoprotein cholesterol levels and pharmaceutical formulations for the same |
| 06/01/2006 | WO2006057448A1 Arylalkanoic acid derivative |
| 06/01/2006 | WO2006057389A1 Novel transcriptional factor phosphorylated by amp protein kinase and gene thereof |
| 06/01/2006 | WO2006057346A1 Ameliorant for renal insufficiency |
| 06/01/2006 | WO2006057270A1 Nitrogeneous tricyclic compound |
| 06/01/2006 | WO2006057209A1 Pharmaceutical composition having action of lowering blood free fatty acid |
| 06/01/2006 | WO2006057152A1 Therapeutic agent for diabetes comprising protease-inhibiting compound |
| 06/01/2006 | WO2006056854A1 Dibenzyl amine compounds and derivatives |
| 06/01/2006 | WO2006056845A1 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
| 06/01/2006 | WO2006056815A1 Indole-2-carboxylic acid amides |
| 06/01/2006 | WO2006031337A3 Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement |
| 06/01/2006 | WO2006018185A8 Dihydropteridinones for the treatment of cancer diseases |
| 06/01/2006 | WO2005107752A3 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 06/01/2006 | WO2004004656A3 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 06/01/2006 | WO2003025542A3 Immune response associated proteins |
| 06/01/2006 | US20060117414 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 06/01/2006 | US20060116516 2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester; 4-Methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-5-thiazolecarboxylic acid, ethyl ester; Antiinflammatory agents; rheumatic diseases |
| 06/01/2006 | US20060116510 Isoflavone concentrates, as well as methods for their production |
| 06/01/2006 | US20060116505 Glucose and/or fructose transporter naglt1 and its gene |
| 06/01/2006 | US20060116426 Inhibitor for perioperative blood sugar elevation |
| 06/01/2006 | US20060116418 Materials and methods for treating hypercholesterolemia |
| 06/01/2006 | US20060116388 CXCR3 antagonists |
| 06/01/2006 | US20060116385 Novel compounds having selective inhibiting effect at gsk3 |
| 06/01/2006 | US20060116378 e.g. 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-dicyclopenta[a,g]naphthalene; serotonine (5-HT) reuptake inhibitor, alpha 2-adrenoceptor antagonist; antidepressant, anxiolytic agent; Parkinson's disease, eating disorders, psychosis, obesity |
| 06/01/2006 | US20060116366 Spirocyclic ureas, compositions containing such compounds and methods of use |
| 06/01/2006 | US20060116364 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer |
| 06/01/2006 | US20060116362 Nobel compounds having selective inhibiting effect at gsk3 |
| 06/01/2006 | US20060115501 Homogeneously Formulating microdosed active principles |
| 06/01/2006 | US20060115500 Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
| 06/01/2006 | US20060115376 Irradiation in presence of stabilizer; preventing degradation |
| 06/01/2006 | CA2589439A1 Modulators of muscarinic receptors |
| 06/01/2006 | CA2589322A1 Dibenzyl amine compounds and derivatives |
| 05/31/2006 | EP1661898A1 Bicyclic piperazine compound and use thereof |
| 05/31/2006 | EP1661897A1 Pyrrolopyrimidinone derivative |
| 05/31/2006 | EP1661896A1 Pyrrolopyrimidinethione derivative |
| 05/31/2006 | EP1661895A1 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione,maleic acid salt,hydrate as pharmaceutical |
| 05/31/2006 | EP1661890A1 Ppar-activating compound and pharmaceutical composition containing same |
| 05/31/2006 | EP1661889A1 Chemokine receptor antagonist and medical use thereof |
| 05/31/2006 | EP1661879A1 Diphenyl ether compound, process for producing the same, and use |
| 05/31/2006 | EP1661579A2 Method for treating diseases associated with changes of qualitative and/ quantitative composition of blood extracellular dna |
| 05/31/2006 | EP1661574A1 Beta-hydroxy short to medium chain fatty acid polymer |
| 05/31/2006 | EP1661569A1 Compounds effecting glucokinase |
| 05/31/2006 | EP1661568A1 Compounds effecting Glucokinase |
| 05/31/2006 | EP1661567A1 Compounds effecting Glucokinase |
| 05/31/2006 | EP1661564A1 Heterocyclic compounds and their pharmaceutical use |
| 05/31/2006 | EP1661563A1 Compound effecting Glucokinase |
| 05/31/2006 | EP1660509A2 Glucopyranosyloxy- pirazoles, drugs containing said compounds the use and production method thereof |
| 05/31/2006 | EP1660490A1 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 05/31/2006 | EP1660478A1 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| 05/31/2006 | EP1660472A1 Aryl piperidine amides |
| 05/31/2006 | EP1660467A2 Aminofurazan compounds as protein kinase inhibitors |
| 05/31/2006 | EP1660456A2 Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
| 05/31/2006 | EP1660448A1 Indol-2-amides as glycogen phosphorylase inhibitors |
| 05/31/2006 | EP1660428A1 Ppar modulators |
| 05/31/2006 | EP1660131A1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 05/31/2006 | EP1660106A1 Biotherapeutics for mitigation of health disorders from terminalia arjuna |
| 05/31/2006 | EP1660077A1 Indol-6 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 05/31/2006 | EP1660067A1 Methods and materials for treating conditions associated with metabolic disorders |
| 05/31/2006 | EP1660066A1 Pharmaceutical composition comprising a combination of metformin and a statin |
| 05/31/2006 | EP1660062A1 Use of colipase-lipase inhibitors in the preparation of a pharmaceutical composition in order to prevent obesity |
| 05/31/2006 | EP1660044A2 Composition comprising a zeolite compound for treatment of diseases |
| 05/31/2006 | EP1558240B1 Hypoestoxides, derivatives and agonists thereof for use in the treatment and prophylaxis of hyperlipidemia |
| 05/31/2006 | EP1485343A4 Amorphous hmg-coa reductase inhibitors of desired particle size |
| 05/31/2006 | EP1448181B1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 05/31/2006 | EP1392295B1 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes |
| 05/31/2006 | EP1345922B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1343772B1 Thia- and oxazoles and their use as ppars activators |
| 05/31/2006 | EP1328282B1 Efficient method for producing compositions enriched in anthocyanins |
| 05/31/2006 | EP1318997B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317449B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317444B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1296967B1 Benzothiazolyl ppar-gamma modulators |
| 05/31/2006 | EP1268798B1 Anti-angiogenic properties of vascostatin and fragments or variants thereof |
| 05/31/2006 | EP1246789B1 Methods of making optically pure (r)- and (s)- didesmethylsibutramine |
| 05/31/2006 | EP1165110B1 Antagonists of hmg1 for treating inflammatory conditions |
| 05/31/2006 | EP1163238B1 Chemokine recpetor binding heterocyclic compounds |
| 05/31/2006 | EP1090136B1 Mumbaistatin, a process for its production and its use as a pharmaceutical |
| 05/31/2006 | EP1073682B1 Heparanase specific molecular probes and their use in research and medical applications |
| 05/31/2006 | EP0911342B1 Novel protein and process for producing the same |
| 05/31/2006 | EP0840789B1 Transketolase-related protein |
| 05/31/2006 | CN1780840A Pyrazolo 1,5-a pyrimidine derivatives |
| 05/31/2006 | CN1780826A Process for the preparation of (4-hydroxy-6-oxo-tetrahydropyran-2-yl) acetonitrile and derivatives thereof |
| 05/31/2006 | CN1780642A Remedy for diabetes |